Tag: M.W=350-400

Chen, Yong-kang published the artcileStudy of methodology validation of detection sodium content in esomeprazole sodium, Related Products of imidazoles-derivatives, the publication is Huaxue Gongchengshi (2016), 30(4), 67-70, database is CAplus.

In this paper, the at. absorption spectrometry (AAS) method for the determination of sodium in esomeprazole sodium was established. Using the standard curve method, the detection wavelength was 589.0 nm. Exptl. results show that at 589.0 nm the blank solution has no interference with the determination of sodium, linear study shows that the concentration of sodium within 0.5∼4.0 mg·L^-1 range, the absorbance A has a good linear relationship with the concentration of C, and R² is greater than 0.999. By method validation: accuracy, solution stability, repeatability and accuracy are good, at the same time this method has good durability and can be used as the determination method of sodium content in esomeprazole sodium.

Huaxue Gongchengshi published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Related Products of imidazoles-derivatives.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Li, Dan published the artcileQuality control of esomeprazole sodium enteric-coated tablets, Recommanded Product: Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, the publication is Yiyao Daobao (2013), 32(5), 683-685, database is CAplus.

Quality control method for esomeprazole sodium enteric-coated tablets was established. Content of esomeprazole was determined by HPLC, and enantiomer of esomeprazole was identified by normal phase chromatog.

Yiyao Daobao published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Recommanded Product: Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Zhao, Wangdan published the artcileDetermination and Thermodynamic Modeling of Solid-Liquid Phase Equilibrium for Esomeprazole Sodium in Monosolvents and in the (Ethanol + Ethyl Acetate) Binary Solvent Mixtures, Product Details of C17H18N3NaO3S, the publication is Journal of Chemical & Engineering Data (2017), 62(7), 1965-1972, database is CAplus.

Esomeprazole sodium was a proton pump inhibitor (PPI) synthesized using omeprazole sulfide. In this paper, we used a static-analytic method to analyze the solubility of our own synthesis of esomeprazole sodium in Et acetate, acetonitrile, Me iso-Bu ketone, ethanol, methanol, and in the (ethanol + Et acetate) mixtures between 278.15 and 328.15 K. A group of thermodn. models were selected such as the Jouyban-Acree equation, the modified Apelblat equation, and CNIBS/R-K equations. All equations can be well applied and the modified Apelblat equations are relatively better. We determined the thermodn. properties of esomeprazole sodium using the van’t Hoff equation furthermore, including the entropy, Gibbs energy, and enthalpy.

Journal of Chemical & Engineering Data published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C15H21BO3, Product Details of C17H18N3NaO3S.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Bai, Zheng-Wu published the artcileEvaluation and comparison of N-cycloalkylformylated chitosan bis(arylcarbamate)s as chiral selectors for enantioseparation, COA of Formula: C17H18N3NaO3S, the publication is New Journal of Chemistry (2017), 41(19), 10561-10567, database is CAplus.

To systematically study the structural dependence on the properties of N-cycloalkylformylated chitosan bis(arylcarbamate)s, 3,5-dimethylphenylcarbamates of N-cyclopropylformylated, N-cyclobutylformylated, N-cyclopentylformylated and N-cyclohexylformylated chitosans were prepared as chiral selectors. Since both the mol. weights of chitosan and the substituents at the 3- and 6-positions of the phenylcarbamates are identical, the influences of the substituent at the 2-position on the solvent tolerability and enantioseparation performance of the chiral selectors were specifically compared and discussed. The solvent tolerability and enantioseparation performances of the chiral selectors obviously differed with the variation of the substituent at the 2-position of the glucosamine skeleton. Although all the chiral selectors generally showed satisfactory tolerability in Et acetate and acetone, the chiral selector with a three-membered ring exhibited much more preferable tolerability against THF than the others with a four-, five- or six-membered ring. Enantioseparation results revealed that most of the chiral selectors exhibited powerful chiral recognition and enantioseparation abilities, and the chiral selector with a five-membered ring exhibited the best enantioseparation performance. The corresponding coated-type chiral stationary phases prepared from these chitosan-based chiral selectors were able to be complementary with each other and applied as promising chiral separation materials for enantiomeric separations

New Journal of Chemistry published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, COA of Formula: C17H18N3NaO3S.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Xia, Pin-si published the artcileDetermination of related substances in esomeprazole sodium for injection by RP-HPLC, Computed Properties of 161796-78-7, the publication is Zhongnan Yaoxue (2014), 12(11), 1131-1135, database is CAplus.

An RP-HPLC method to determine the related substances in esomeprazole sodium for injection was established. The determination was performed on a Inerstil ODS-3 column (150 mm×4.6 mm, 5 μm), with a mobile phase consisting of a mixture of acetonitrile and phosphate buffer (pH=7.4) and tetrabutylammonium hydrogen sulfate. The column temperature was 30°C at 1.0 mL·min^-1 and the detective wavelength was 280 nm. The related substances were completely separated from the main constituent. Impurity A and B were stable in 24 h under the condition of frozen dark, but impurity C was not stable. Omeprazole and impurity A, B and C had good linearity at 0.0633-2.1108 μg·mL^-1 (r=1.000), 0.1465-1.9538 μg·mL^-1 (r=1.000), 0.1587-1.9835 μg·mL^-1 (r=0.9999), 0.0576-3.8388 μg·mL^-1 (r=0.9996) resp. The recoveries were at 91%-105%, and RSDs were less than 5%, which could be meet the requirements. The method can be used for the quality control of esomeprazole sodium for injection.

Zhongnan Yaoxue published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C4H5BN2O2, Computed Properties of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Zhu, Ling-Ling published the artcilePoor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications, Quality Control of 161796-78-7, the publication is World Journal of Gastroenterology (2012), 18(24), 3167-3172, database is CAplus and MEDLINE.

Aim: To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined protective medications. Methods: A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital, School of Medicine, Zhejiang University. The hospital has 2300 beds and 2.5 million outpatient visits annually. Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011. Concomitant use of proton-pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RA) and muco-protective drugs (MPs) were analyzed. A defined daily dose (DDD) methodol. was applied to each MP. A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs (NSAIDs), corticosteroids and clopidogrel and warfarin] or intestinal protective drugs (misoprostol, rebamipide, teprenone and gefarnate). Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records. The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients. Results: Prescriptions for aspirin users receiving PPIs, H2RA and MPs (n = 1039) accounted for only 3.46% of total aspirin prescriptions (n = 30 015). The ratios of coadministration of aspirin/PPI, aspirin/H2RA, aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%, 0.12%, 0.40% and 0.12%, resp. No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs, H2RA or MPs. The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs (2.82% vs. 0.40%, P < 0.05) and aspirin/H2RA (2.82% vs. 0.12%, P < 0.05). The values of DDDs of MPs in descending order were as follows: gefarnate, hydrotalcite > teprenone > sucralfate oral suspension > -glutamine and sodium gualenate granules > rebamipide > sucralfate chewable tablets. The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows: rebamipide (0.47%), teprenone (0.91%), -glutamine and sodium gualenate granules (0.92%), gefarnate (0.31%), hydrotalcite (1.00%) and sucralfate oral suspension (0.13%). Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were: rebamipide (0.010%), PPI/rebamipide (0.027%), teprenone (0.11%), PPI/teprenone (0.037%), gefarnate (0.017%), and PPI/gefarnate (0.013%). No prescriptions were found containing coadministration of aspirin and other NSAIDs. Among the 3196 prescriptions containing aspirin/clopidogrel, 3088 (96.6%) prescriptions did not contain any GI protective medicines. Of the 389 prescriptions containing aspirin/corticosteroids, 236 (60.7%) contained no GI protective medicines. None of the prescriptions using aspirin/warfarin (n = 22) contained GI protective medicines. Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin. The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin, resp. Conclusion: The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications. Actions should be taken to address this issue.

World Journal of Gastroenterology published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C15H15OP, Quality Control of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Yu, Min published the artcileHPLC peak positioning of omeprazole sulphone and esomeprazole sodium, Formula: C17H18N3NaO3S, the publication is Zhongguo Kangshengsu Zazhi (2012), 37(10), 773-775, 788, database is CAplus.

The eluotropic series of the main component esomeprazole sodium and its impurity omeprazole sulfone in different HPLC conditions were determined The HPLC methods adopted Welch Materials Xtimate-C₈ column (4.6mm×250mm, 5 μm), Phenomenex b-sil- C₈ column (4.6mm×250mm, 5 μm), Zorbax Eclipse XDB-C₈ column (4.6mm×250mm, 5 μm), Kromasil-C₈ column (4.6mm×150mm, 5 μm), Spherisorb-C₈ column (4.6mm×150 mm, 5 μm), Welch Materials Welchrom-C₈ column (4.6mm×250mm, 5 μm), 0.01 mol/L disodium hydrogen phosphate solution (adjust pH to 7.6 with phosphoric acid)-acetonitrile (67:33) as mobile phase, the flow rate was 1.0 mL per min. The detection wavelength was 280 nm. And the injection volume was 20 μL. The eluotropic series of esomeprazole sodium and omeprazole sulfone in HPLC were influenced by the column, not by the other conditions. The main influencing factor for the eluotropic series of esomeprazole sodium and omeprazole sulfone in HPLC was column.

Zhongguo Kangshengsu Zazhi published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C3H5F3O, Formula: C17H18N3NaO3S.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Zhang, Juan published the artcileSynthesis of substituted phenylcarbamates of N-cyclobutylformylated chitosan and their application as chiral selectors in enantioseparation, Application of Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, the publication is Analyst (Cambridge, United Kingdom) (2016), 141(14), 4470-4480, database is CAplus and MEDLINE.

The goal of this study was to develop new chiral stationary phases (CSPs) with high chiral recognition capability and high compatibility with the so-called nonstandard solvents. Seven new chitosan bis(phenylcarbamate)-(N-cyclobutylformamide) derivatives were synthesized from chitosan with high degree of deacetylation as a starting material. The corresponding chiral stationary phases (CSPs 1-7) were prepared with the chitosan derivatives as chiral selectors (CSs). The enantioseparation capability of CSPs 1-7 was evaluated by HPLC with nineteen analytes. In comparison with the CSPs of cellulose tris(3,5-dimethylphenylcarbamate) (CDMPC) and amylose tris(3,5-dimethylphenylcarbamate) (ADMPC), the prepared CSPs generally demonstrated excellent enantioseparation capability, particularly for the CSP derived from chitosan bis(3-chloro-4-methylphenylcarbamate)-(N-cyclobutylformamide). Also, the CSPs in the present study could sep. some analytes better, making them complementary for enantioseparations with the CSPs of CDMPC and ADMPC. The tolerability of the CSP with the best enantioseparation capability to organic solvents was studied. It could work in pure Et acetate, pure chloroform, and a normal phase containing 70% THF, which are prevented from enantioseparation by the coating type CSPs of CDMPC and ADMPC. As these chitosan derivatives were almost insoluble in most organic solvents, the corresponding CSPs can work in a wide range of mobile phases. The influence of the position and electron effects of Me and chloro groups introduced onto the CSs and the composition of mobile phases on enantioseparation is also discussed.

Analyst (Cambridge, United Kingdom) published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N2O6, Application of Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Qin, Xu-feng published the artcileDetection and control of impurities in esomeprazole sodium for injection, Synthetic Route of 161796-78-7, the publication is Shandong Huagong (2014), 43(3), 21-25, database is CAplus.

Objective: To establish a method to determine and confirm the structures of the impurities in esomeprazole sodium for injection. Method: HPLC method was adopted. The determination was performed on Agilent chromatog. (model: 1260, detector: G1315D), ZORBA EXTEND-C18 (250 mm × 3.0 mm, 5 μm) column was used. The flow rate was 1.0 mL·min^-1 with UV detective wavelength at 280 nm, the column temperature was 35°C, gradient elution; the structure was identified by NMR and mass spectrum. Results: The imparity peaks and esomeprazole sodium peak were effectively separated when the sample was forcedly destroyed, no matter change the proportion of mobile phase, column temperature, flow rate, or different chromatog. column models and manufacturers, the separation degree accords with regulation. Conclusion: The method has been developed and validated of the detection and control of impurities in esomeprazole sodium for injection, and the structures of impurities have been confirmed. This method is selective, specific, good durable. It is suitable for structure confirmation, detection and control of impurities in esomeprazole sodium for injection.

Shandong Huagong published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Synthetic Route of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Khomenko, T. M. published the artcileAn efficient procedure for the synthesis of Esomeprazole using a titanium complex with two chiral ligands, Quality Control of 161796-78-7, the publication is Russian Journal of Organic Chemistry (2008), 44(1), 124-127, database is CAplus.

A procedure has been proposed for the selective preparation of Esomeprazole [(S)-I] via asym. oxidation of the corresponding prochiral sulfide in the presence of a catalytic complex derived from titanium(IV) isopropoxide and two different chiral ligands, di-Et D-tartrate and (R)-N,N-dimethyl-1-phenylethanamine.

Russian Journal of Organic Chemistry published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Quality Control of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem